Stent Prizes revised

March 31, 2019
Stent Rates Revised ,welcome move
Dr K K Aggarwal
New Delhi, March 31, 2019 :

Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary/ National Pharmaceutical Pricing Authority: New Delhi, the 29th March 2019

In continuation of the notifications issued by National Pharmaceutical Pricing Authority,  Department of Pharmaceuticals, Ministry of Chemical and Fertilizers vide S.O. 639(E) dated 12.02.2018 and S.O. 1464(E) dated 02.04.2018, regarding the fixation of ceiling price of the Coronary  Stents as specified in column no. (2) mentioned in the table below; after considering the  Wholesale  Price  Index  (WPI)  @  4.2662 per cent for the year 2018 over 2017, it has been decided to revise the ceiling prices of Coronary Stents as mentioned in column no. (4) in the table below, exclusive of Goods and Services Tax as applicable, and unit specified in column (3) with effect from 01.04.2019, as under:

TABLE

Sl No Coronary Stents

( Sl No. 31 in Schedule-I of the DPCO, 2013)

Unit

(in Number)

Ceiling Price

(in Rs.)

(1) (2) (3) (4)
1 Bare Metal Stents 1 8,261
2 Drug Eluting Stents (DES) including metallic DES and Bioresorbable Vascular  Scaffold (BVS)/ Biodegradable Stents 1 30,080

(a)            All the existing manufacturers/importers of Coronary Stents having MRP lower than the ceiling price specified in column (4) in the above table (plus Goods and Services Taxes as applicable, if any), may revise the existing MRP of Coronary Stent, on the basis of WPI @ 4.2662% for year 2018 in accordance with Paragraph 16(2) of DPCO, 2013, read with Para 13(2) of DPCO, 2013.

(b)            The manufacturers/importers of Coronary Stents may add Goods and Services Taxes only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (4) of the aforesaid table.

 (c)        As per Para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer/importers, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.

(d)        The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955.

Stay informed with the latest news from HealthySoch. Sign up today for exclusive insights and updates!

We promise we never spam!

Leave a Reply

Your email address will not be published.

Columnists

HealthySoch

Don't Miss

Immunotherapy – Evolving cancer care during COVID 19 pandemic

Author : Dr. N Aditya Murali, Consultant – Medical &

Create menstrual health awareness and management

Mumbai, December 10, 2021: Today on World Human Rights Day,